Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medicinal cannabis for pain and symptoms in endometriosis
ACTRN12624000328572Phase 3Recruiting
- Sponsor
- Western Sydney University
- Start
- Apr 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nabiximols and cannabidiol in endometriosis (3 arms), sponsored by Western Sydney University. Primary endpoints: Overall pelvic pain severity, Adverse events and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
nabiximolscannabidiol
03
Conditions
endometriosis
Beyond the preview
Go deeper on ACTRN12624000328572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000328572.